

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : G01N 33/68, 33/577		A2	(11) International Publication Number: WO 93/09437 (43) International Publication Date: 13 May 1993 (13.05.93)
(21) International Application Number: PCT/US92/09220 (22) International Filing Date: 29 October 1992 (29.10.92)			(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).
(30) Priority data: 785,804 31 October 1991 (31.10.91) US			Published <i>Without international search report and to be republished upon receipt of that report.</i>
(71) Applicant: MATRITECH, INC. [US/US]; 763D Concord Avenue, Cambridge, MA 02138 (US).			
(72) Inventors: BEAUSANG, Lee, Anne ; 67 Priscilla Avenue, Norfolk, MA 02046 (US). LIDGARD, Graham, P. ; 77 Kingsbury Street, Wellesley, MA 02141 (US). MILLER, Thomas, E. ; 701 Oak Street, Franklin, MA 02038 (US).			
(74) Agent: KELLEY, Robin, D.; Testa, Hurwitz & Thibeault, Exchange Place, 53 State Street, Boston, MA 02109 (US).			

(54) Title: NUCLEAR MATRIX PROTEIN FLUID ASSAY**(57) Abstract**

Disclosed is a method for detecting and quantitating soluble nuclear matrix proteins in body fluids and extracellular media. The method is useful for monitoring the viability of cells and tissue, for evaluating the progress of a disease or its treatment, and for evaluating the cytotoxicity of unknown compounds. Also disclosed are methods for inducing the release of nuclear matrix proteins in soluble form from cells.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

WO 93/09437

PCT/US92/09220

1

NUCLEAR MATRIX PROTEIN FLUID ASSAYBackground of the Invention

This invention relates generally to the use of body fluid-soluble nuclear matrix proteins as cellular markers. More particularly, the invention relates to a method of monitoring the degree of cell death in a tissue by monitoring the level of interior nuclear matrix proteins and/or fragments thereof released from cells in a body fluid-soluble form.

Cell death occurs as a function of healthy tissue homeostasis, as well as a result of disease or injury to the tissue. Detectable changes in the rate of cell death in a tissue therefore can provide an indication of the tissue's status. In normal growing tissue, for example, changes in the rate of cell death can indicate a new developmental stage. Alternatively, a sudden detected change in cell death in adult tissue can signal an injury to the tissue and also provide information on the type of injury. Previously, clinical assessment of tissue viability has required presentation of clinical symptoms and a visual inspection of the tissue itself, requiring observation of the morphology of cells in a tissue sample, and/or an indirect estimation of cell death by measuring changes in tissue/organ size. While the state of the art of morphological observation has advanced significantly, reliance on histological observation of an abnormality requires that the abnormal cells comprise part of the tissue sample tested. Early stages of a malignancy therefore can be particularly difficult to detect by this method. Biochemical

WO 93/09437

PCT/US92/09220

- 2 -

assessments of cell or tissue viability also generally have been difficult to interpret, primarily because in many instances cell death occurs in individual cells which are intimately intermixed with viable cells in a 5 sample.

There exists a need for reliable means of monitoring the degree of cell death in a tissue which does not rely on histology or tissue biopsy. A 10 particularly useful method would be one wherein the rate of cell death could be monitored in a body fluid assay. It is anticipated that the ability to accurately monitor tissue-specific cell death in a fluid assay would have significant impact on the study 15 of tissue development and cell kinetics, as well as on many different clinical applications. For example, the method may be used to monitor the progress of a disease or injury associated with cell death, as well as to monitor the efficacy of a therapy for an affected 20 tissue. The method also may be used to monitor the effect of the therapy on unaffected, normal tissue. In addition, the method may be used to evaluate a compound's cytotoxicity.

25 Recently, methods have been disclosed for extracting and isolating the normally highly insoluble interior nuclear matrix proteins from cells. Interior nuclear matrix proteins are proteins from within the boundaries of the nuclear matrix, termed "interior" 30 nuclear matrix proteins, which are substantially free of chromatin proteins, and intermediate filaments, collectively termed "exterior" nuclear matrix proteins (see Penman et al., US Pat No. 4,882,268, the disclosure of which is hereby incorporated by

WO 93/09437

PCT/US92/09220

- 3 -

reference). In the method, the cell nucleus is isolated, the cytoskeleton proteins and chromatin are removed, the "nuclear matrix" is isolated, and the interior and exterior components of the nuclear matrix are separated. The nuclear matrix-intermediate filament complex comprises a specific fraction of cell protein constituting less than five percent of the total protein and six percent of the total DNA of the cell. The interior nuclear matrix comprises about one percent or less of the total cellular protein. It contains many proteins that differ according to cell type, and is highly enriched with type-specific antigens including cell-type and transformation-specific proteins that had not been detected using prior art procedures. It also contains the lamina and nuclear pore complex proteins. The separation method makes use of the unique properties of the nuclear matrix to achieve separation from substantially all other cell constituents. The method is simple, rapid, reproducible, achieves a high degree of purity, and is applicable to essentially all types of cells.

The method of Penman et al. has enabled the art to identify and isolate cell type-specific and transformation-specific interior nuclear matrix proteins of sufficient purity to allow antibodies to be made. These antibodies then can be used to detect cell type-specific interior nuclear matrix proteins in a sample, as disclosed in US application Serial No. 214,022, filed June 30, 1988, to be issued as U.S. Patent No. _____, the disclosure of which is incorporated herein by reference. As used therein and here, the term "cell-type" is understood to refer to cells of various different tissues such as neural,

WO 93/09437

PCT/US92/09220

- 4 -

glial, muscle, liver, mesenchymal, and different types of epithelia and endothelia, as well as malignant cell forms and cells having an altered genomic expression profile caused by viral infection or other factors.

5

It is an object of this invention to provide a method for monitoring the degree of cell death in a body fluid assay by monitoring the level of body fluid-soluble interior nuclear matrix proteins in a fluid.

10 Another object of the invention is to provide a method for quantifying the body fluid-soluble interior nuclear matrix proteins released from cells and present in a cell compatible fluid. Still another object of the invention is to provide a method for evaluating a

15 therapy, or the progress of a disease associated with cell death by monitoring the degree of cell death in an affected tissue. Another object of the invention is to provide a method for assessing the toxicity of compounds by assessing their ability to induce cell

20 death. Still another object of the invention is to provide a method for inducing the release of body fluid-soluble nuclear matrix proteins from eucaryotic cells. These and other objects and features of the invention will be apparent from the description and

25 claims which follow.

WO 93/09437

PCT/US92/09220

- 5 -

Summary of the Invention

It now has been discovered that interior nuclear matrix proteins or soluble fragments thereof are released in soluble form from cells undergoing cell death. As used herein, "cell death" is understood to include both apoptosis ("programmed" cell death), and necrosis. Moreover, it also now has been discovered that these soluble forms of interior nuclear matrix proteins can be quantitated in a fluid and used to monitor the degree, or rate, of cell death in a tissue. The method of the invention also may be used to distinguish between the types of cell death occurring. The presence of these proteins and protein fragments in solution in a body fluid soluble form is unexpected as the molecules comprise part of an insoluble nuclear complex under standard physiological conditions. The discovery of these proteins released in soluble form from dying cells allows one to use the soluble interior nuclear matrix proteins as biochemical monitors of tissue-specific cell death in fluid assays. The method is rapid and quantitative and can be used to evaluate the viability of cells and tissue, to evaluate progress of a disease and/or its treatment, to evaluate the cytotoxicity of unknown compounds and to study the kinetics of cell death. The discovery also provides an alternative method for purifying interior nuclear matrix proteins from cells.

The method of the invention involves detecting the concentration of body fluid-soluble interior nuclear matrix proteins or fragments thereof released from cells and comparing this concentration to a known standard. The concentration of these proteins in a

WO 93/09437

PCT/US92/09220

- 6 -

body fluid sample will be indicative of the degree of cell death in that tissue. Fluid samples are collected at discrete intervals and detected by means, for example, of an immunoassay. The concentrations of characteristic proteins then are compared, with changes in concentrations being indicative of the changes in the rate of cell death. In addition, certain proteins may be identified as cell type-specific and/or as cell death type-specific. Exemplary body fluids include blood, serum, plasma, urine, semen, spinal fluid, saliva, ascitic fluid, peritoneal fluid, sputum, tissue swabs, and body exudates such as breast exudate.

In one embodiment of the invention, the method may be used to evaluate the progress of a disease. For example, the method may be used to monitor the progress of a malignancy such as, for example, a carcinoma, adenoma, sarcoma, lymphoma, or myeloma. Here the rate of cell death in a malignant tissue may be monitored by quantitating the level of soluble nuclear matrix protein released from the malignant cells. Alternatively, the method also may be used to monitor the progress of tissue disorders resulting in altered cell death, such as results from tissue atrophy, hyperplasia, cirrhosis, hypoxia, ischaemia and benign tumor growths. Injured tissue also can be assessed by this method, including direct cell trauma such as from membrane-active chemicals and toxins or resulting from direct physical trauma, such as, for example, hyperthermia, hypoxia and ischemia/reperfusion, radiation or complement-mediated autolysis.

In another embodiment of the invention, the method may be used to monitor the efficacy of a therapy. Here a therapeutic agent or procedure (e.g., radiation

WO 93/09437

PCT/US92/09220

- 7 -

therapy) is administered to a patient and, thereafter, the concentration of soluble nuclear matrix proteins or fragments are detected in body fluid samples drawn from the patient at predetermined intervals. These 5 concentrations then are compared to each other and to those in samples tested before administration of the therapy. The changes in concentration of one or more interior nuclear matrix proteins detected among the samples compared will be indicative of the therapy's 10 efficacy. For example, a therapeutic agent capable of selectively destroying malignant cells can cause an increase in soluble nuclear matrix proteins released from the tumor cells, followed by a reduction in the level of these proteins detected as the number of 15 malignant cells fall. The method also may be used to monitor the effect of a given therapy on the viability of normal, unaffected tissue. For example, a number of cancer therapies, including radiation and chemotherapy, target rapidly proliferating cell populations and 20 therefore can affect normally proliferative cell populations such as bone marrow progenitor cell populations and intestinal epithelial cells. The effect of the therapy on these cell populations can be evaluated by monitoring the level of soluble interior 25 nuclear matrix protein released from these cells. It is anticipated that a single body fluid sample can provide information on the viability of both the affected tissue and normal tissue provided that cell-type specific proteins can be monitored for each 30 tissue. Similarly, the method also may be used to evaluate the efficacy of complementary therapeutic agents designed to protect normal tissue from the effects of the therapy.

WO 93/09437

PCT/US92/09220

- 8 -

In yet another embodiment of the invention the method may be used to evaluate the type of cell death occurring and to study its kinetics. For example, nuclear matrix proteins or protein fragments may be 5 identified that are preferentially released in soluble form by cells undergoing either apoptosis or necrosis. The rate of release of these proteins or protein fragments then may be monitored to investigate cell death kinetics.

10

In still another embodiment of the invention the method may be used to monitor the status of a cell culture and/or to assess the cytotoxicity of a compound by monitoring the levels of soluble interior nuclear 15 matrix proteins or protein fragments released from these cells. Finally, the method also may be used to induce release of body fluid-soluble interior nuclear matrix proteins from intact cells, using compounds capable of inducing apoptosis, such as, for example, 20 cytokines. A particularly useful cytokine is TNF (Tumor Necrosis Factor). This embodiment of the invention may be used to enhance identification of particular interior nuclear matrix proteins. It further may be used as part of a protocol to isolate 25 soluble interior nuclear matrix proteins or protein fragments. Novel nuclear matrix proteins may be obtained by this method, as well as known or novel proteins useful as antigenic determinants in antibody production. Finally, the method of the invention may 30 be useful as part of a protocol to identify candidate compounds useful as cancer chemotheapeutic agents (see infra.).

WO 93/09437**PCT/US92/09220**

- 9 -

These and other embodiments and features of the invention will be apparent from the specification, drawings and claims, which follow.

WO 93/09437

PCT/US92/09220

- 10 -

Brief Description of the Drawings

FIGURE 1 lists the levels of body fluid-soluble interior nuclear matrix protein quantitated in various 5 normal and malignant tissue sample supernatants;

FIGURE 2 lists the levels of body fluid-soluble interior nuclear matrix proteins quantitated in sera isolated from cancer patients and normal blood donors;

10 FIGURE 3 is a graphic representation of the soluble nuclear matrix proteins detected by the 22/18 and 41/7 antibody combinations following the release of these nuclear matrix proteins from necrotic and apoptotic 15 cells;

FIGURE 4 (A and B) are graphic representations of the effect of TNF (tumor necrosis factor) on soluble nuclear matrix protein released from cultured cells;

20 FIGURE 5 is a graph correlating nuclear matrix protein release with cell density;

25 FIGURE 6 is a graph correlating TNF dose with the release of soluble nuclear matrix protein detected by the 41/7 antibody combination;

30 FIGURE 7 is a graphic representation of the effect of Doxorubicin on soluble nuclear matrix protein release and cell viability.

WO 93/09437

PCT/US92/09220

- 11 -

Detailed Description

In the description which follows, the generalized method for monitoring cell death by quantitating the body fluid-soluble interior nuclear matrix proteins released from cells into a fluid is disclosed. The method involves the selection of interior nuclear matrix proteins to form a substantially pure preparation of interior nuclear matrix proteins, herein referred to as a NM preparation, and the use of this preparation to generate nuclear matrix protein-specific antibodies. Preferably the antibodies are cell-type specific. The antibodies also may be cell death-type specific. Next, methods are disclosed for designing assays useful for monitoring cell death with these antibodies in different fluid assays, including serum. Methods also are disclosed for inducing the release of these proteins in soluble form from cells.

Biologically relevant mechanisms of cell death generally are classified as either apoptosis or necrosis, primarily on the basis of histological studies. The two mechanisms generally are distinguished functionally and morphologically. Apoptosis generally is understood to characterize the coagulative necrosis of single cells, so-called "programmed" cell death. It characteristically affects individual cells in an asynchronous fashion, and generally is not accompanied by an inflammatory reaction. Apoptosis is involved in the programmed focal elimination of cells that accompanies embryonic and fetal development, and in regulating the size of organs and tissue in adult life. Apoptosis also has been identified in pathological tissue atrophy, as well

WO 93/09437

PCT/US92/09220

- 12 -

as in a variety of malignant neoplasms, and following exposure to a range of injurious agents, a number of which are associated with DNA damage, e.g., radiation, hyperthermia, and a variety of carcinogens and cancer-
5 chemotherapeutic agents. Cell-mediated immune reactions also are thought to induce apoptosis, and this mechanism of cell death also is associated with diseases highlighted by cell-mediated immune destruction of tissues, including so-called auto-immune
10 diseases, cirrhosis, and a number of viral diseases including hepatitis and the like.

By contrast, necrosis generally is understood to refer to the progressive degeneration of cell structure
15 that occurs after death caused by severe, injurious changes in environmental conditions. Necrosis typically affects groups of contiguous cells and an inflammatory reaction usually develops in the adjacent viable tissue. Among the many known examples of
20 necrosis are cell destruction following severe hypoxia and ischemia, in tissue undergoing autolysis in vitro, and cell destruction following severe hyperthermia, or exposure to numerous membrane-active chemicals, toxins and reactive oxygen metabolites.

25 Morphologically, necrotic cells tend to appear swollen, with eosinophilic cytoplasm and indistinct cell boundaries. Cells undergoing apoptosis are characterized by chromatin condensation and by the
30 formation of membrane-bound apoptotic bodies.

WO 93/09437

PCT/US92/09220

- 13 -

All eukaryotic cells, both plant and animal, have a nucleus surrounded by the cell cytoplasm. The nucleus contains DNA complexed with protein and termed chromatin. The chromatin, with its associated proteins, constitutes the major portion of the nuclear mass. The chromatin is organized by the internal protein skeleton of the nucleus referred to herein as the interior nuclear matrix. A method for extracting and selectively purifying the highly insoluble interior nuclear matrix protein from cells recently has been discovered (see U.S. Pat. No. 4,882,268 incorporated herein by reference). It also has been discovered that certain interior nuclear matrix proteins are tissue and cell type-specific and that their expression also can be altered in a transformation- or disease-specific manner in affected cells. This alteration in expression pattern makes these proteins ideal markers for detecting and identifying abnormal cell growth, particularly for detecting malignancies, (see USSN 214,022, filed June 30, 1988, to be issued as U.S. Patent No. _____, incorporated herein by reference). Following the methods disclosed in the U.S. 4,882,268 and 4,885,236 patents, interior nuclear matrix proteins can be selectively purified and used as antigenic determinants to raise antibodies which may be used to detect the presence of these proteins in cell samples or as part of the cellular debris from destroyed cells.

A detailed description for isolating interior nuclear matrix proteins is disclosed in USSN 214,022 filed June 30, 1988, to be issued as U.S. Patent No. _____, and incorporated by reference herein (see supra). Broadly, the isolation procedure involves the following:

WO 93/09437

PCT/US92/09220

- 14 -

1. Isolation and separation of cells.
2. Separation of soluble cell proteins from the nucleus and cytoskeleton by extraction of membrane lipids and soluble proteins with a non-ionic detergent-physiological salt solution.
- 5 3. Separation of cytoskeleton proteins from the nucleus by solubilization of the insoluble cell material from step 2 in either 0.25 M ammonium sulfate, pH 6.8, a detergent-sodium deoxycholate solution, or other gentle extraction buffer.
- 10 4. Separation of chromatin from the nuclear matrix by digestion of the insoluble material from step 3 with DNase I and RNase in a physiological buffer, and elution of the DNA-containing nucleosomes with 0.25 M ammonium sulfate solution buffered to pH 6.8 or other gentle extraction buffer.
- 15 5. Separation of the interior nuclear and "exterior" nuclear matrix proteins by dissolution of the insoluble material from step 4 in a buffer containing between 5 and 10 M urea, preferably 8 M urea, or other suitable solubilizing agent, and aggregation of the exterior proteins by dialysis into physiological buffer.
- 20
- 25

In a variation of this procedure, and as used herein, the cytoskeleton proteins and chromatin are removed together by digesting the insoluble material from step 2 with DNase and RNase, then extracting with 0.25 M ammonium sulfate at pH 6.8. Further purification of the interior nuclear proteins can be

WO 93/09437

PCT/US92/09220

- 15 -

performed using standard methods known to those skilled in the art, including HPLC, FPLC, chromatofocusing and the like.

5 The matrix preparation is biochemically and morphologically pure by several biochemical criteria. Freedom from contamination permits a clear and detailed analysis of the matrix proteins by gel electrophoresis. It previously has been shown that electropherograms of
10 a NM preparation show markedly different patterns in different cell types. These patterns are unique, specific and reproducible. It further has been discovered that this pattern allows selection of one or more proteins characteristic of the cell type and
15 useful as antigenic determinants. (See, for example, U.S. Pat. No. 4,882,268 and USSN 214,022.) As shown therein, individual matrix proteins useful as cell-type discriminators often comprise less than 0.01% of the cell's total protein. Antibodies raised against these
20 proteins then can be used to identify cell-type specific nuclear matrix proteins in samples. Moreover, antibodies raised against these proteins also may be used to distinguish the type of cell death occurring (see infra.)

25 As indicated above, the method of the invention involves monitoring cell death by quantitating the soluble interior nuclear matrix proteins released from cells into a fluid. As will be appreciated by those
30 skilled in the art, any means for specifically identifying and quantifying the protein is contemplated. The current state of the art for identifying proteins in solution is by means of an immunoassay, wherein an antibody capable of binding

WO 93/09437

PCT/US92/09220

- 16 -

specifically to the protein of interest is used to identify the protein in solution and the amount of bound complex formed then is determined.

5 Antibody methodologies are well understood and described in the literature. A more detailed description of their preparation can be found, for example, in Practical Immunology, Butt, W.R., ed., Marcel Dekker, New York, 1984. Broadly, antibodies may
10 be raised against one or more proteins in a NM preparation by immunizing a suitable animal with an immunogenic preparation under conditions sufficient to induce antibody production in that animal. Monoclonal antibodies then can be obtained by fusing suitable
15 antibody producing cells such as spleen or lymph node cells to myeloma cells and screening the fusion products for nuclear reactivity against the immunogen source (e.g., cell line or particular cell type determinant) using standard techniques. A detailed
20 protocol for screening for particular cell type determinants can be found in USSN 214,022, incorporated by reference hereinabove.

25 The currently preferred method for quantitating body fluid-soluble nuclear matrix proteins is by detecting the proteins with interior nuclear matrix protein-specific antibodies. The antibodies may be monoclonal or polyclonal in origin, and may be produced by standard methodologies. The nuclear matrix proteins
30 used as immunogens may be prepared by the method disclosed by Penman et al. (U.S Pat. No. 4,882,268, see infra). Alternatively, interior nuclear matrix proteins may be isolated by inducing their release in soluble form from cells as described herein, and

WO 93/09437

PCT/US92/09220

- 17 -

selectively extricating them from the supernatant. Proteins or protein fragments also may be recombinantly expressed from nucleic acids using standard recombinant DNA technology. Antibodies to one or more of these 5 proteins then are raised using standard methods. The antibodies then are exposed to the body fluid sample under conditions sufficient to allow specific binding of the antibody to its specific nuclear matrix protein, and the amount of complex formed then detected.

10

A variety of different forms of immunoassays currently exist, all of which may be adapted to quantitate body fluid-soluble interior nuclear matrix proteins released from cells. Of the various 15 immunoassay formats available, one of the most sensitive is the sandwich technique. In this method, two antibodies capable of binding the analyte of interest are used: one immobilized onto a solid support, and one free in solution, but labeled with 20 some easily detectable chemical compound. Examples of chemical labels that may be used for the second antibody include radioisotopes, fluorescent compounds, and enzymes or other molecules which generate colored or electrochemically active products when exposed to a 25 reactant or enzyme substrate. When samples containing analyte (e.g., body fluid-soluble interior nuclear matrix protein or protein fragments) are placed in this system, the analyte binds to both the immobilized antibody and the labelled antibody. The result is a 30 "sandwich" immune complex on the support's surface. The analyte is detected by washing away nonbound sample components and excess labeled antibody and measuring the amount of labeled antibody complexed to analyte on the support's surface. The sandwich immunoassay is

WO 93/09437

PCT/US92/09220

- 18 -

highly specific and very sensitive, provided that labels with good limits of detection are used. A detailed review of immunological assay design, theory and protocols can be found in numerous texts in the 5 art, including Practical Immunology, Butt, W.R., ed., Marcel Dekker, New York, 1984.

Immunoassay design considerations include preparation of antibodies (monoclonal or polyclonal) 10 having sufficiently high binding specificity for their antigen that the specifically-bound antibody-antigen complex can be distinguished reliably from nonspecific interactions. The higher the antibody binding specificity, the lower the antigen concentration that 15 can be detected. The choice of tagging label for the second antibody also will depend on the detection limitations desired. Enzyme assays (ELISAs) typically allow detection of a colored product formed by interaction of the enzyme-tagged complex with an enzyme 20 substrate. Alternative labels include radioactive or fluorescent labels. The most sensitive label known to date is a chemiluminescent tag where interaction with a reactant results in the production of light. Useful labels include chemiluminescent molecules such as 25 acridium esters or chemiluminescent enzymes where the reactant is an enzyme substrate. When, for example, acridium esters are reacted with an alkaline peroxide solution, an intense flash of light is emitted, allowing the limit of detection to be increased 100 to 30 10,000 times over those provided by other labels. In addition, the reaction is rapid. A detailed review of chemiluminescence and immunoassays can be found in Weeks, et al., (1983) Methods in Enzymology 133:366-387. Other considerations include the use of

WO 93/09437

PCT/US92/09220

- 19 -

microtiter wells or column immunoassays. Column assays may be particularly advantageous where rapidly reacting labels, such as chemiluminescent labels, are used. The tagged complex can be eluted to a post-column detector 5 which also contains the reactant or enzyme substrate, allowing the subsequent product formed to be detected immediately.

The invention may be better understood from the 10 following nonlimiting examples wherein interior nuclear matrix proteins are prepared from two different cell lines (breast tumor and cervical tumor cells), polyclonal and monoclonal antibodies are made and tested for reactivity and sensitivity, and immunoassays 15 are performed on sera, and tissue and cell culture supernatants. Apoptosis generally is induced herein by placing cells in serum-free media, by exposure to a cytokine (e.g., TNF) or by exposing cells to particular cytotoxic agents. Necrosis is induced herein by freeze 20 thawing (hyperthermia.) Using the methods disclosed herein, and variations of these methods, cell death can be quantitated and monitored in vivo and in vitro by analyzing body fluids or body fluid compatible solutions, e.g., extracellular culture media, for 25 soluble nuclear matrix proteins or protein fragments. Generally, the method involves preparation of a standard ("dose response") curve for the nuclear matrix protein to be monitored, and against which samples can be prepared. As indicated earlier, the status of 30 multiple different tissues also may be assessed in a single fluid sample, by monitoring the concentrations of different cell-type specific nuclear matrix determinants in the sample.

WO 93/09437

PCT/US92/09220

- 20 -

Also disclosed is a method for inducing release of interior nuclear matrix proteins in soluble form from cells, using compounds capable of inducing cell death. Currently preferred compounds include cytokines such as

5 TNF which induce apoptosis. Inducing release of interior nuclear matrix proteins from cells into a fluid can enhance evaluation of a tissue's status. It also is envisioned that the method may be useful as part of a protocol for identifying and purifying novel
10 interior nuclear matrix proteins, for preparing proteins and protein fragments for use as antigens in antibody preparations, and for identifying candidate compounds useful in cancer chemotherapy (see infra.)

15

I. Antibody Development

A. Isolation of Nuclear Matrix.

20 Nuclear matrix proteins are isolated herein essentially according to the method of Penman and Fey, disclosed in US Patent No. 4,882,268, the disclosure of which is incorporated herein by reference. Briefly, desired cell lines are grown to confluence in
25 Dulbecco's Modified Eagle's medium (DME) (Mediatech, Washington, DC) with 10% fetal calf serum (Hazelton) in T225 flasks. The media then is removed from the flask and the cells washed twice with phosphate buffered saline (PBS) (0.1M Phosphate, 0.15M NaCl pH 7.4). The
30 washed cells then are removed from the flask by incubation with 0.1% trypsin/EDTA (Irvine Scientific, Santa Ana, CA) in PBS at 37°C for 15 minutes. The resulting cell suspension is poured into 10 ml of the original media and pelleted by centrifugation at 1500Xg

WO 93/09437

PCT/US92/09220

- 21 -

for 15 min. The media then is aspirated off and the cells resuspended, and counted. The cells are again pelleted and extracted twice with cold RSB/Majik buffer (0.1M NaCl, 10mM MgCl₂, 10mM TRIS, 0.5% Na 5 Deoxycholate, 1.0% Tween-20, 1.2mM PMSF pH 7.4) and spun at 2100xg for 15 min at 4°C. 10ml of RSB/Majik is used for every 1x10E7 cells. At room temperature the extracted cells are resuspended in digestion buffer (50mM NaCL, 300mM sucrose, 0.5% Triton X-100, 10mM 10 PIPES, 3mM MgCl₂, 1mM EGTA, 1.2mM PMSF). DNase I and RNase A (Boehringer Mannheim, Germany) are added to a concentration of 100 ug/ml and the solution incubated with agitation for 20-40 min. Sufficient 2M ammonium sulphate is added to make a final concentration of 15 0.25M and after 5 min the solution is centrifuged at 3700xg for 15 min. The resulting pellet is resuspended in disassembly buffer (8M urea, 20mM MES, 1mM EGTA, 1.2mM PMSF, 0.1mM MgCl₂, 1% 2-mercaptoethanol pH 6.6) and dialyzed against 4 liters of assembly buffer (0.15M 20 KCl, 25mM Imidazole, 5mM MgCl₂, 2mM dithiothreitol, 0.125mM EGTA, 0.2mM PMSF pH 7.1) overnight at room temperature. The resulting suspension is then centrifuged in an ultracentrifuge at 100,000g for one hour. The supernatant containing the interior nuclear 25 matrix proteins (referred to herein as the NM preparation) then can be stored frozen at -80°C until required.

For the examples disclosed herein, interior nuclear 30 matrix proteins were isolated from three human tumor cell lines, all available through the American Type Culture Collection (ATCC, Rockville, MD): T-47D (breast tumor cell line); and ME-180 and CaSki (cervical tumor cell lines).

WO 93/09437

PCT/US92/09220

- 22 -

B. Immunization Protocols**1. Polyclonal antibodies**

5 Polyclonal antisera can be raised against the NM preparation using standard methodologies, such as those disclosed in numerous texts available in the art and known to those generally skilled in the art. In this example, rabbits were immunized with the NM preparations first in Freund's complete adjuvant

10 (Gibco, Grand Island, NY) and then every month with NM with incomplete adjuvant for three months. Rabbit sera and sera from mice prior to fusion were used as polyclonal antisera and were shown by standard western blot technique to be reactive with the NM preparations.

15

2. Monoclonal Antibodies

Monoclonal antibodies can be raised against the NM proteins also using standard methodologies, such as those disclosed in numerous texts available in the art and known to those generally skilled in the art. In this example, Balb/c by J (The Jackson Laboratory, Bar Harbor, ME) mice were immunized with the nuclear matrix protein preparations in the following manner:

25 (a) Lymph Node Protocol: Animals are injected in the two hind foot pads and hind quarters using the following protocol: day 1, Antigen and complete Freund's Adjuvant; day 4, antigen and saline in hindquarters only; day 13, the animal is sacrificed and the popliteal lymph nodes removed for fusion.

30 (b) Spleen Protocol: Animals are injected every two weeks intraperitoneally for 6-8 injections, then boosted intravenously once four days prior to

WO 93/09437

PCT/US92/09220

- 23 -

sacrifice and removal of the spleen. Injection #1 is with complete Freund's adjuvant, #2 is incomplete adjuvant, and subsequent injections are with saline.

5 C. Fusions

Hybridomas of the spleen or lymph node cells are fused essentially accordingly to the method of Kohler and Milstein (1975) Nature 256:495, the disclosure of 10 which is herein incorporated by reference. Briefly, a suspension of spleen or lymph node cells are fused with cells of a mouse myeloma cell line using polyethylene glycol (PEG, Boehringer Mannheim). Resulting positive hybridomas then are cloned a minimum of three times to 15 achieve monoclonality. Mouse myeloma cell lines used herein were SP2/0-Ag14 or P3X63Ag8.653 (ATCC, Rockville, MD.)

1. Antibody Screening (Cell Assay/Reactivity

20 Assay):

Growth positive wells from the hybridomas can be screened for nuclear reactivity against the cell line that is the source of the immunogen using the minifold I dot blot apparatus (Schleicher & Schuell, 25 Keene, NH) and standard procedures. Briefly, a 4.5" by 3" piece of nitrocellulose 0.45 μ m filter membrane (Bio-Rad, Richmond, CA) and two pieces of similar size Whatman 3MM paper are soaked in distilled water and PBS for 10min each and then assembled in the dot blot 30 apparatus. 1x10E6 cells stored frozen in 10% DMSO culture media are washed in PBS and 100 μ l per well of a 10ml cell suspension are added with the vacuum suction on. The cells then are washed with 100 μ l of digestion buffer, 400 μ l of PBS with 0.05% Tween-20, 100 μ l of 0.5%

WO 93/09437

PCT/US92/09220

- 24 -

nonfat dried milk (Carnation) in PBS (to block nonspecific binding), and 400 μ l of PBS Tween-20. With the vacuum turned off, 100 μ l of supernatant from growing hybrids are incubated with the cells for 5 30 min. The supernatant then is removed via vacuum suction and the cells again washed with 400 μ l of PBS Tween-20. With the vacuum off, 100 μ l of a goat anti-mouse biotin conjugate in 1% horse serum PBS (e.g., VECTASTAIN, Vector labs, Burlingame, CA) is added to 10 each well and incubated for 15min. The cells then are washed with 400 μ l of PBS Tween-20 and incubated with the Vectastain Avidin-HRP substrate for 3min. The reaction is stopped with tap water and the membrane removed from the apparatus and soaked in water. The 15 membrane then is sandwiched between two glass plates with microscope slide resin and examined under the microscope. Wells showing positive nuclear staining are considered positive and these hybrids are chosen to be further cloned.

20

2. Tissue Immunohistochemistry

Positive clones can be evaluated for human tissue reactivity using cryostat cut frozen tissue sections and the avidin/biotin peroxide staining procedure.

25 (Vectastain Elite ABC kit, Vector Laboratories, Burlingame, CA)

3. Ascites Production

Mice are pristane (2,6,10,14

30 Tetramethylpentadecane) primed by injecting 0.5ml pristane into the peritoneal cavity. Seven to ten days later 5x10E6 cells in one ml of serum free media are injected into the peritoneal cavity. Ascites fluid then is collected from each mouse twice and pooled.

WO 93/09437

PCT/US92/09220

- 25 -

Monoclonal anti-NM antibodies are purified from mouse ascites by protein G purification (Genex Corp., Gaithersburg, MD) and stored at 4°C until required.

5 D. Biotinylation of Antibodies

Antibodies can be labelled following standard techniques. In these examples, antibodies are biotinylated conventional procedures. Briefly, 10 purified antibodies (herein, monoclonal anti-NM antibodies purified from mouse ascites) are dialyzed overnight against 0.1M sodium bicarbonate pH 8.4 and the concentration adjusted to 1.0mg/ml. Biotin-X-NHS (0.5ml CalBiochem, Inc., San Diego, CA) 1.5mg/ml in 15 DMSO, then is added to 5ml of the antibody solution and reacted for 2hr at room temperature with rocking in the dark. 2M Tris-HCL pH 8.0 (0.5ml) is added and incubated for a further 30 min. PBS-merthiolate (0.01%) containing 1% BSA then is added (5 ml) and the 20 mixture dialyzed three times against the PBS-Merthiolate.

II. Assays

25 A. Sandwich Immunoassay (ELISA)

A standard immunoassay can be performed to generate dose response curves for antigen binding, for cross reactivity assays, and for monitoring assays. The data 30 is generated with a standard preparation of NM antigen, and is used as the reference standard when body fluids are assayed. In these examples both ELISAs and radioimmunoassays were performed.

WO 93/09437

PCT/US92/09220

- 26 -

1. Immunoassay (Well Assay)

5 Microtitre plates (Immulon II, Dynatech, Chantilly, VA) are coated with purified antibody at 5 to 15ug/ml
in PBS at pH 7.4 for 1hr or overnight and then washed 3
x with 300 μ l PBS. The plates then are blocked with 10%
normal goat serum in PBS for 1hr at room temp and
washed 3 x with 300 μ l of PBS.

10 Here, samples were assayed by pipetting 100 μ l of sample per well, and incubating for 1hr at RT. The wells were washed with 3 x 300 μ l PBS. 100 μ l of 1.25 to 10 μ g/ml of a biotinylated antibody was added to each well, incubated for 1hr at RT and washed with 3 x 300 μ l
15 of PBS. 100 μ l of a 1:1000 dilution of streptavidin-horseradish peroxidase conjugate (The Binding Site Ltd., Birmingham, UK) was added to each well and incubated for 1hr and then washed with PBS. 100 μ l of peroxidase substrate (citrate, phosphate, OPD-H₂O₂) was
20 added to each well and incubated for 20min. The reaction was stopped by adding 50 μ l of 1M H₂SO₄ to the wells. The optical density was read on a plate reader at 490nm.

25 Concentrations of NM antigen were determined by preparing a reference concentration of NM and preparing a standard dilution curve to compare with the unknown samples.

30 2. IRMA (Immunoradiometric Assay)

(a) Iodination of Streptavidin.
10 μ g of streptavidin (Sigma, Inc., Cincinnati) in 2 μ l of 0.05M phosphate pH 7.4 was added to 10 μ l of

WO 93/09437

PCT/US92/09220

- 27 -

0.25M phosphate pH 7.4 in a microcentrifuge tube and 1mCi of ^{125}I (NEN-DUPONT, Wilmington, DE) in 10 μl was added. Immediately 10 μl of 100mg chloramine-T trihydrate (Sigma, Inc.) in 50ml of distilled water was 5 added, mixed, and reacted for 25sec. The reaction was stopped by mixing for 20sec with 50 μl of 40mg Cysteamine (2-mercaptoethlyamine)(Sigma, Inc.) and 5mg KI in 50ml of 0.05M phosphate pH 7.4. 0.5ml of 1% BSA in PBS pH 7.4 was added and the material was 10 fractionated on a 10ml sephadex G-100 column (Pharmacia, Sweden) pre-equilibrated with the BSA PBS buffer. 30 by 0.5ml fractions were collected and 10 μl was diluted to 1ml of the BSA/PBS buffer for each fraction. 100 μl of the diluted fraction was counted on 15 a LKB gamma counter set for ^{125}I . The specific activity was calculated and routinely fell between 85 to 100uCi/ug. The mid fractions of the protein peak were used in the sandwich immunoassay.

20 (b) Sandwich Radioimmunoassay.

The microtitre breakaway wells (Immulon II Removewell strips, Dynatech, Chantilly, Va) are coated and blocked as in the ELISA assay. The samples, 25 standard or sera, are routinely measured by incubating 100 μl in the wells for 1hr at RT washing on a plate washer with 3 x 300 μl of PBS and then incubated with the biotinylated antibody (2-10 $\mu\text{g}/\text{ml}$ in 10% goat serum) for 1hr at RT and washed again. The bound biotinylated 30 antibody is detected with the ^{125}I -streptavidin. 200,000 to 300,000 cpm (77% counter efficiency) in 100 μl is added to each well and incubated for 1hr at RT and washed again. The bound fraction is detected by counting the radioactivity in an LKB gamma counter.

WO 93/09437

PCT/US92/09220

- 28 -

The concentration can be determined by comparing the counts obtained against a reference preparation.

B. Dot Blot Detection of NM.

5

Antibody reactivity with NM proteins can be assessed by dot blot detection assays, using standard methodologies and apparatus (e.g., Schleicher & Schuell). Nitrocellulose membranes are soaked in Tris buffered saline, (TBS, 50mM TRIS, 150mM NaCl, pH 7.6) and NM preparation applied at varying concentrations of protein to a series of wells and incubated for 1hr at room temperature (e.g., T-47D NM supernatant at 10 μ g/ml, 1 μ g/ml and 100ng/ml). The blocked wells then are washed with 2 x 200 μ l of TBS and then blocked with 100 μ l 10% normal goat serum in TBS for 1hr at room temperature. The blocked wells then are washed again with 2 x 200 μ l of TBS and 100 μ l of culture supernatant containing nuclear reactive antibody to be tested is added to their respective wells and incubated for 1hr at room temperature. The wells then are washed with 2 x 200 μ l of TBS and 100 μ l of a dilution series of alkaline phosphatase conjugated goat anti-mouse IgG (Bio-Rad, Richmond, CA) (e.g., 1:1000, 1: 5000, or 1:10000) added to the relevant wells and incubated for 1hr. The wells then are washed with 2 x 200 μ l of TBS followed by addition of enzyme substrate (BCIP/NBT, Kirkgaard and Perry, Gaithersburg, MD, e.g., 100 μ l) in Tris buffer containing Levamisole (Vector, Inc., Corpus Christi, TX.) A fifteen minute incubation generally is sufficient. The reaction can be stopped by washing with distilled water and the product detected.

WO 93/09437

PCT/US92/09220

- 29 -

III. Soluble Antigen Preparation from Dying Cells
(Serum Deprivation).

Cell lines are grown to confluence in tissue
5 culture flasks by standard culturing techniques. The
media then is replaced with serum-free media and the
cells placed in a 37°C incubator with 5% CO₂ for 7 to
14 days, depending on the cell line. At the end of the
incubation the media is collected and centrifuged at
10 14,000xg to remove cellular debris, and the supernatant
stored frozen.

Where human tissue is used, normal and tumor, the
soluble interior nuclear matrix proteins can be
15 released in a similar fashion. Tissue is removed from
a donor, flash frozen in liquid nitrogen within 10min
to 4hrs after removal and stored at -70°C until
required. When ready to be used, the tissue is chopped
20 into 0.1 to 0.3 cm cubes as it thaws using aseptic
techniques in a laminar flow hood and placed in a T150
flask containing serum free media containing Fungizone
and gentamycin. In general, 2-4g of tissue are used per
100ml media in the T150 flask. The flask containing
the tissue then is incubated for 4-7 days at 37°C with
25 5% CO₂. After incubation the media is collected from
the flasks, centrifuged at 14,000xg for 20min and the
supernatant stored at -20°C until needed.

IV. Representative Assays

30

Reactivity Assays

Immunoblot studies for anti-nuclear matrix
reactivity were performed with monoclonal antibodies

WO 93/09437

PCT/US92/09220

- 30 -

raised against T-47D nuclear matrix to identify those having strong reactivity with the T-47D antigen. Among those identified were three antibodies referred to herein as 200-4, 203-37, and 304-41. All antibodies 5 exhibited a positive reaction. The intensity of reaction was best at the higher concentrations of secondary antibody, and no reaction was observed in the absence of antigen.

10 Using the same assay conditions these three antibodies, 200-4, 203-37, and 304-41, all showed reactivity with the supernatant from T-47D dying cells, but not with the media alone, demonstrating the release of soluble antigen into the cell culture supernatant.
15 Anti-KLH (keyhole limpet hemocyanin) monoclonal antibody used as a negative control, showed no reactivity with the spent supernatant confirming the specificity of the antibody reactions. Similar results were obtained with polyclonal rabbit sera raised 20 against the nuclear matrix proteins.

Table I below displays the binding results for assays performed with different antibodies raised against the two different cervical tumor cell line NM 25 antigen preparations (ME-180 and CaSKi). The 100-series antibodies are those raised against the ME-180 NM immunogen; the 300-series are those raised against CaSKi-NM immunogen.

WO 93/09437

PCT/US92/09220

- 31 -

TABLE I

		SOLUTION Ab					
		107-7	302-18	302-22	302-29	302-47	307-33
5							
<u>CAPTURE Ab</u>							
	107-7	NO RXN	NO RXN	NO RXN	RXN	NO RXN	RXN
	302-18	NO RXN	RXN	RXN	RXN	RXN	RXN
	302-22	NO RXN	RXN	NO RXN	NO RXN	NO RXN	RXN
10	302-29	NO RXN	RXN	NO RXN	NO RXN	NO RXN	RXN
	302-47	NO RXN	NO RXN	NO RXN	NO RXN	NO RXN	NO RXN
	307-33	NO RXN	NO RXN	NO RXN	RXN	NO RXN	NO RXN

15

As can be seen from the table, twelve of the thirty-six combinations tested result in a positive reaction. A positive reaction means that the two antibodies react with different epitopes on the same molecule. Only one antibody, 302-18, reacted in combination with itself.

Dose Response Assays

25 The first sandwich assay was obtained using antibodies 200.34 and 200-4 on nuclear matrix proteins isolated by the method of Penman and Fey (Table II) and on cell culture supernatant from dying cells (Table III). The cell line T-47D was used as the 30 source of antigen for both experiments and demonstrated that a dose response curve can be obtained with these assay conditions.

WO 93/09437

PCT/US92/09220

- 32 -

Table II shows the data generated using a standard ELISA immunoassay and purified NM, isolated by the Amethod of Penman et al. Table III shows the data generated under the same conditions, but using the supernatant of dying cells as the antigen source. The cell line T-47D was used as the antigen source for both experiments and two antibodies, previously shown to have strong reactivity with the T-47D antigen by dot blot assay, were used (Ab 200-34, solid phase; Ab 200-4 as soluble antibody).

Table II

15	<u>Protein Concn. in NM prep.</u>	OD		
		rep 1	rep 2	mean
	10 μ g/ml	0.186	0.187	
	1 μ g/ml	0.036	0.032	0.034
	0.1 μ g/ml	0.021	0.009	0.015
20	0.0	0.00	0.003	0.001

Table III

25	<u>Concentration of supernatant</u>	Mean OD		<u>SD</u>
	Undiluted	0.150		0.015
	1:2	0.071		0.010
30	1:4	0.026		0.003
	1:8	0.013		0.005
	No Sup			
35	2:1 undiluted	0.401		0.015
	1:2	0.145		0.006
	1:4	0.05		0.002
	1:8	0.017		0.003
	No Sup	0.003		0.002
40		0.000		

The data show that reliable dose response curves can be generated using these assay conditions to quantitate soluble NM antigen in solution. Following 45 this protocol, other antibody combinations can be

WO 93/09437

PCT/US92/09220

- 33 -

tested for their ability to detect and quantitate body fluid-soluble nuclear matrix proteins and protein fragments.

5 Dose response evaluation results of two of these antibody combinations are shown in Table IV, below, using ME-180 cell culture supernatant as the antigen source. Each assay shows dose dependent detection of antigen in the tissue culture supernatant,
10 demonstrating the ability of the assay to quantitate soluble interior nuclear matrix protein released from dying cells.

Table IV

15 Antibody 107-7 solid phase, 302-29 soluble antibody, ME-180 supernatant

	<u>Concentration of supernatant</u>	<u>Mean OD</u>	<u>SD</u>
20	2:1	0.501	0.013
	undiluted	0.274	0.018
	1:2	0.127	0.006
25	1:4	0.067	0.006
	1:8	0.035	0.009
	1:16	0.021	0.007
	No Sup	0.000	

30 Antibody 107-7 solid phase, 307-33 soluble antibody, ME-180 supernatant.

	<u>Concentration of supernatant</u>	<u>Mean OD</u>	<u>SD</u>
35	3:1	0.906	0.009
	3:2	0.456	0.011
	3:4	0.216	0.007
	3:8	0.099	0.005
40	3:16	0.052	0.002
	3:32	0.031	0.005
	No Sup		

WO 93/09437

PCT/US92/09220

- 34 -

Next, interior nuclear matrix protein quantification was tested in supernatant from a variety of dying tumor tissues. Here, tumor and normal tissues were allowed to die in media as described supra.

5 Supernatants were assayed in various configurations of sandwich assays. The results are shown in Fig. 1, where all values are in units/gm, using ME-180 antigen as standard. As can be seen from Fig. 1, antigen is released from each of the dying tissues, and the three
10 assays are measuring different antigens. As expected, the increased cell death in tumor tissue is reflected in a higher average antigen value quantitated in cancer tissue versus normal tissue. In addition, significant differences in antigen quantities are seen in the
15 different tissue sources, indicating that the soluble antigen quantities present in the supernatant vary in a cell-type specific manner.

Figure 2 shows the results of an analogous experiment performed using serum samples from cancer patients and normal blood donors. As for Fig. 1, ME-180 cell antigen was the standard. Results are reported in units/ml. A control experiment diluting supernatant antigen into serum and then quantitating
25 the protein in solution indicates that serum has little or no effect on the assay. As can be seen in Fig. 2, like the results shown in Fig. 1, serum samples from cancer patients reflect a higher rate of cell death as indicated by the quantifiably higher levels of antigen detected in these samples compared with those detected
30 in the normal blood serum samples.

WO 93/09437

PCT/US92/09220

- 35 -

Apoptosis and Necrosis

1. In this example, both apoptosis and necrosis were induced and the effect of this injury on nuclear matrix 5 protein release tested. In this experiment ME-180 cells (cervical tissue culture cell line) were suspended into serum free medium. Necrosis was induced in one aliquot by freezing the cells at -20°C, overnight. Cells were allowed to necrose for seven 10 days at 37°C with 5% CO₂. Apoptosis was induced in a second aliquot by serum deprivation for seven days at 37°C with 5% CO₂. Supernatants from each aliquot then were harvested and assessed by immunoradiometric assays using 302-22/302-18 ("22/18") and 204-41/107-7 ("41/7") 15 antibody combinations. As shown in Fig. 3, the 22/18 assay shows specificity for apoptosis: ten times more 22/18 antigen is released by apoptotic cells (serum deprived, non-frozen) than by necrotic cells (frozen). By contrast, the 41/7 assay measures an antigen that is 20 released substantially equally by both necrotic and apoptotic cells.

2. In this example apoptosis was induced by exposing MCF 7 cells (breast carcinoma cell line, ATCC, 25 Rockville, MD) to Tumor Necrosis Factor (TNF alpha). MCF 7 cells were seeded into 12 individual T-25 flasks in 35ml of Dulbecco Modified Media (DME) with 5% fetal calf serum and SeraXtend. The cells were grown at 37°C and 5% CO₂ until 60-70% confluency. Cell supernatants 30 were removed and split into two groups of six:

WO 93/09437

PCT/US92/09220

- 36 -

Group 1: Control - cell supernatants were replaced with fresh media.

5 Group 2: TNF - Cell supernatants were replaced with fresh media containing 500U/ml recombinant human TNF-alpha (Cellular Products, Inc. (Buffalo, NY)).

At discrete intervals: 2 hours, 8 hours, 24 hours, 10 48 hours, and 72 hours, supernatants were removed, spun down at 1200 rpm and frozen at -80°C. Cells remaining adhered were used for slides and PAP-stained (using standard cell staining techniques). Supernatants were assessed by immunoradiometric assay using the 22/18 or 15 302.29/107.07 ("29/7") antibody combination. As seen in Fig. 4 cell treatment with TNF induces the release of nuclear matrix protein into the supernatant soon after exposure (by 20 hours), whereas the untreated cells do not. Fig. 4A is assayed with the 22/18 20 combination; Fig. 4B with the 29/7 combination. In addition, histological evaluation of the stained cells verified that the TNF-treated cells showed the characteristics of apoptosis (chromatin condensation, cytoplasmic blebbing).

25

Dose vs. Density Experiment

Here, MCF7 cells (breast carcinoma, adherent) were grown in a one stage cell factory (Nunc) in DME 30 complete (5% FCS + SerXtend) at 37°C and 5% CO₂. These cells then were harvested, resuspended in serum free Minimal Essential Medium contain fungizone and gentamycin (MEM), counted, and seeded into T150 flasks with 35 mls serum free media at different cell 35 densities.

WO 93/09437

PCT/US92/09220

- 37 -

The cells were allowed to die for 7 days at 37°C and 5% CO₂. The supernatants were drawn off, spun down at 1000 rpm to remove cell fragments. All supernatants were assayed by immunoradiometric assays using the 5 22/18, and by the 41/7 antibody combination in an ELISA.

For all nuclear matrix proteins tested, release was essentially directly related to cell density (See 10 Fig. 5). The result is significant as these preliminary data suggest that nuclear matrix protein release is consistent and quantifiable, and values detected can be correlated with cell number.

15 Cytotoxic Reagent Assay

1. In this experiment, the effect of increasing concentrations of TNF on the release of the 41/7 nuclear matrix protein was investigated. MCF7 tissue 20 culture cells growing at 37°C and 5% CO₂ in tissue culture medium were exposed to different concentrations of TNF by replacing the tissue culture media with media containing TNF. As shown in Fig. 6, the quantity and rate of release of the 41/7 nuclear matrix protein is 25 related to the dose of TNF added, particularly at doses greater than 1.0 units/ml TNF (Fig. 6).

2. In this experiment, the effect of a known cancer chemotherapeutic agent (Doxorubicin, Sigma Inc.) on 30 soluble nuclear matrix protein release into extracellular fluid was assessed.

A standard curve for live cells was established with MCF7 cells (breast carcinoma, adherent). Cells 35 were seeded into 6 well plates in 2 mls of DME complete

WO 93/09437

PCT/US92/09220

- 38 -

(5% FCS + SerXtend) with 0.5 micrograms/ml mitomycin C (Sigma, Inc., Cincinnati) to prevent any cell growth.

After incubating overnight at 37°C, 200 µl of 3-[4,
5 5 Dimethylthiazol-2-4] 2, 5-diphenyltetrazolium bromide), MTT, stock solution (5mg/ml MTT in phosphate-buffered saline, Sigma, Inc.) were added to each well. After the plates were incubated for four hours at 37°C and 5% CO₂, the supernatants were aspirated off and 4
10 mls of DMSO (dimethyl sulfoxide) were added to solubilize remaining crystals. This was drawn off and the absorbance was read in the spectrophotometer at 562 nm against a blank of straight DMSO.

15 Cells were treated with Doxorubicin as follows: MCF7 cells were seeded into 6 well plates at a density of 1.3x10⁵ cells/well in 2 mls DME complete. After 72 hours of growth at 37°C and 5% CO₂, the supernatants were aspirated off and replaced with DME complete
20 containing 450nM Doxorubicin.

At 1, 24, 48, 72, and 96 hours, the supernatants were removed and frozen at -20°C to assay later. After replacing the supernatant with a fresh 2 ml of DME
25 complete, the number of live cells was determined using the same procedure as for the standard curve. The cell supernatants were assayed by ELISA, using the 41/7 antibody combination. The dose values obtained from these ELISAs were plotted along with standard curve
30 data to observe correlations between the assay measurement of remaining live cells and nuclear matrix protein release (See Fig. 7)

As evidenced by Fig. 7, cell viability appears to
35 be inversely related to nuclear matrix protein released.

WO 93/09437

PCT/US92/09220

- 39 -

TNF-Induced Release of Nuclear Matrix Protein

The present invention also may be used to prepare a NM preparation from cells by inducing their release 5 from cells in soluble form with an appropriate agent such as TNF. Generally, a protocol similar to that of the cytotoxic reagent assay may be used to induce protein release. Cells are grown essentially to confluence, and the supernatant then is replaced with 10 DME complete, 250U/ml TNF. After an appropriate incubation period, the supernatant is drawn off and the soluble nuclear matrix protein extracted from solution by standard protein separation methods, for example, by chromatography on a cationic exchange column or an 15 affinity column, such as an immunoaffinity column. Once purified, the NM preparation may be maintained as a frozen solution until ready to be used. The NM proteins so prepared can be used in immunoassay standards and for the production of further monoclonal 20 and polyclonal antibodies. It is also proposed that these proteins can be used to evaluate their ability to bind to other compounds and thus identify compounds capable of interfering with the nuclear function of particular nuclear matrix proteins. Compounds capable 25 of specifically binding to and interfering with the nuclear function of cancer-specific nuclear matrix proteins, for example, may be useful as cancer chemotherapeutic agents.

30 The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the

WO 93/09437

PCT/US92/09220

- 40 -

invention being indicted by the appended claims rather than by the forgoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

5

WO 93/09437

PCT/US92/09220

- 41 -

What is claimed is:

1. A method for determining the degree of cell death in a tissue, said method comprising the step of:

5 detecting the concentration of body fluid-soluble nuclear matrix protein, or fragments thereof, released from the cells of said tissue, said concentration being indicative of the degree of cell
10 death in said tissue.

2. The method of claim 1 wherein said cell death occurs by apoptosis.

3. The method of claim 1 wherein said cell death occurs by necrosis.

15 4. The method of claim 1 wherein the concentration of said nuclear matrix protein is detected in a sample of body fluid.

5. The method of claim 1 for use in evaluating the status of a disease associated with cell
20 death, said method comprising the additional steps of:

25 (a) repeating, at intervals, the step of detecting the concentration of body fluid-soluble nuclear matrix protein or fragments thereof; and

WO 93/09437

PCT/US92/09220

- 42 -

(b) comparing said detected concentrations, wherein changes in said detected concentrations are indicative of the status of the disease.

5 6. The method of claim 5 wherein the disease is a malignancy.

7. The method of claim 6 wherein the malignancy is a carcinoma, sarcoma, lymphoma or myeloma.

8. The method of claim 1 for use in evaluating the efficacy of a therapy, said method comprising the additional steps of:

(a) administering a therapeutic agent or procedure to a patient;

(b) repeating, at intervals, the step of detecting the concentration of body fluid-soluble nuclear matrix protein or fragments thereof; and

(c) comparing said detected concentrations, wherein changes in said concentrations are indicative of the effect of the therapeutic agent or procedure.

9. The method of claim 8 wherein said therapy induces cell death.

10. The method of claim 8 wherein said therapeutic agent or procedure is a cancer therapeutic agent or procedure.

WO 93/09437

PCT/US92/09220

- 43 -

11. The method of claim 1 wherein the nuclear matrix protein is detected in a sample of body fluid selected from the group consisting of blood, serum, plasma, urine, semen, spinal fluid, ascitic fluid, peritoneal fluid, saliva, sputum, tissue swabs, and body exudates.
12. The method of claim 11 wherein said body exudate is breast exudate.
13. The method of claim 1 wherein the step of detecting comprises the steps of:
 - (a) exposing a sample comprising a said body fluid to antibodies specific for said nuclear matrix protein under conditions sufficient to allow specific binding of said antibodies to said protein or fragments thereof in said sample; and
 - (b) measuring the amount of antibody-nuclear matrix protein complex formed by said specific binding, the amount being indicative of the concentration of body fluid-soluble nuclear matrix protein in said sample.
14. The method of claim 13 wherein said nuclear matrix protein-specific antibodies are monoclonal antibodies.
15. The method of claim 13 wherein said nuclear matrix protein-specific antibodies are obtained by:

WO 93/09437

PCT/US92/09220

- 44 -

- (a) selectively obtaining nuclear matrix proteins from cells; and
- (b) raising antibodies to said nuclear matrix proteins.

5 16. The method of claim 15 wherein said antibodies raised in step b comprise a polyclonal sera.

17. The method of claim 15 wherein said antibodies raised in step b comprise monoclonal antibodies to selected nuclear matrix proteins
10 of step a.

18. A method for inducing release of body-fluid-soluble nuclear matrix protein from cells, the method comprising the steps of:

15

- (a) exposing a cell sample in a liquid medium to a compound which induces release of interior nuclear matrix protein; and
- (b) detecting a nuclear matrix protein or a fragment thereof in said liquid medium released from the cells in said sample.

20 19. The method of claim 18 wherein said compound is a cytokine.

20. The method of claim 19 wherein said compound is tumor necrosis factor.

21. A method for evaluating the cytotoxicity of a compound, the method comprising the steps of:
25

WO 93/09437

PCT/US92/09220

- 45 -

- (a) exposing a cell sample to a compound to be tested;
- 5 (b) detecting the concentration of soluble nuclear matrix protein or a fragment thereof released from cells in said sample; and
- 10 (c) comparing the detected concentration to the concentration of soluble nuclear matrix protein released from cells in the absence of said compound.

22. A method for detecting the release of soluble nuclear matrix protein or a soluble fragment thereof from cells, the method comprising the step of:

- 15 (a) obtaining a sample of the liquid medium surrounding cells,
- (b) detecting the presence of soluble nuclear matrix protein, or fragments thereof, in said medium, released from said cells.

20 23. Isolated body fluid soluble nuclear matrix protein isolated by a method comprising steps of:

- (a) exposing cells to an agent capable of inducing release of body fluid soluble nuclear protein,
- 25 (b) collecting a sample of the liquid medium surrounding said cells,

WO 93/09437

PCT/US92/09220

- 46 -

(c) selectively extracting the body fluid soluble nuclear matrix proteins present in said liquid.

24. The method of claim 1, 21 or 22 wherein said
5 nuclear matrix proteins are characteristic of
said cells.

25. The method of claim 5 wherein said disease
induces tissue hyperplasia, cirrhosis,
hypoxia, ischaemia or complement-mediated
10 autolysis.

26. The method of claim 5 wherein said disease is
an autoimmune disease or a viral disease.

27. The method of claim 1 where said cell death
results from direct cell trauma, such as from
chemicals, toxins or direct physical trauma.
15

28. The method of claim 8 or 10 wherein said
therapy comprises radiation therapy or
chemotherapy.

WO 93/09437

PCT/US92/09220

1/8

FIG. 1.1

<u>SAMPLE</u>	<u>SAMPLE #</u>	<u>ANTIBODY COMBINATIONS</u>			
		<u>302-22</u> <u>302-18</u>	<u>302-33</u> <u>107-7</u>	<u>302-29</u> <u>302-18</u>	<u>302-29</u> <u>107-7</u>
NORMAL	1	0.0	0.0	0.0	0.0
NORMAL	2	0.0	0.0	0.0	0.0
NORMAL	3	0.0	0.0	0.0	0.0
NORMAL	4	0.0	0.0	0.0	0.0
NORMAL	5	0.0	0.0	0.0	0.0
NORMAL	6	0.0	0.0	0.0	0.0
NORMAL	7	0.0	0.0	0.0	0.0
NORMAL	8	0.0	0.0	0.0	0.0
NORMAL	9	0.0	0.0	0.5	0.0
NORMAL	10	0.0	0.7	1.2	0.0
NORMAL	11	0.0	0.0	0.0	0.0
NORMAL	12	0.0	0.0	0.0	0.2
NORMAL	13	0.0	0.7	0.0	0.3
NORMAL	14	0.0	1.3	0.0	0.6
NORMAL	15	0.0	5.3	0.0	1.7
NORMAL	16	0.0	1.4	0.0	0.4
NORMAL	17	0.0	2.2	0.0	1.0
NORMAL	18	0.0	2.0	0.0	0.0
NORMAL	19	0.0	3.0	0.0	0.4
NORMAL	20	0.0	2.3	0.0	1.3
NORMAL	21	0.0	3.9	0.0	0.6
NORMAL	22	0.0	8.2	0.0	1.3
NORMAL	23	0.0	4.0	0.0	0.8
NORMAL	24	0.0	4.3	0.0	0.7
NORMAL	25	0.0	9.1	0.0	0.6
NORMAL	26	0.0	5.9	0.0	0.2
NORMAL	27	0.0	20.6	0.0	6.0
NORMAL	28	0.9	2.2	0.9	0.7
NORMAL	29	1.4	5.0	0.0	1.0
NORMAL	30	1.4	3.5	1.4	1.2
NORMAL	31	1.9	10.1	3.9	1.0
NORMAL	32	2.1	3.3	0.0	6.3
NORMAL	33	2.8	1.5	0.0	0.0
NORMAL	34	4.1	6.9	6.6	0.8
NORMAL	35	4.2	0.0	5.4	0.0
NORMAL	36	11.0	1.2	5.6	0.0
BLADDER CA	37	0.0	0.0	0.0	0.0
BLADDER CA	38	36.7	1.6	0.0	0.0
BLADDER C	39	0.0	0.0	0.0	0.0
COLON CA	40	8.8	8.9	8.6	7.0
COLON CA	41	18.2	28.4	20.8	24.3
COLON CA	42	18.1	28.6	19.5	17.9
COLON CA	43	14.2	11.6	15.5	8.1
COLON CA	44	9.5	12.8	13.3	6.8
COLON CA	45	5.1	6.4	4.1	0.9
COLON CA	46	4.9	3.7	5.1	2.4

WO 93/09437

PCT/US92/09220

2/8
FIG. 1.2

<u>SAMPLE</u>	<u>SAMPLE #</u>	<u>ANTIBODY COMBINATIONS</u>			
		<u>302-22</u> <u>302-18</u>	<u>302-33</u> <u>107-7</u>	<u>302-29</u> <u>302-18</u>	<u>302-29</u> <u>107-7</u>
COLON CA	47	30.8	28.3	65.3	27.3
COLON CA	48	96.2	17.5	82.4	20.2
COLON CA	49	3.3	4.7	0.0	0.0
COLON CA	50	10.1	11.7	8.3	10.3
COLON CA	52	2.4	5.7	64.7	0.0
COLON CA	53	6.7	5.1	5.5	0.5
COLON CA	54	5.1	6.0	1.3	1.8
COLON CA	55	3.9	13.1	7.1	2.3
COLON CA	56	62.4	9.6	52.4	5.8
COLOREC CA	57	14.0	58.2	15.2	41.3
ENDOMETRIUM C	58	7.6	10.3	106.0	6.8
ENDOMETRIUM C	59	2.7	4.7	1.8	1.9
ENDOMETRIUM C	60	7.9	9.4	8.2	7.1
LUNG CA	61	10.0	13.4	10.7	9.3
LUNG CA	62	9.5	11.9	11.0	7.9
LUNG CA	63	11.3	19.0	13.5	16.2
LUNG CA	64	6.5	16.7	8.5	7.8
LUNG CA	65	12.6	20.8	14.9	11.0
OVARY CA	66	14.3	21.1	17.4	16.9
OVARY CA	67	7.0	16.4	9.9	8.9
OVARY CA	68	8.9	11.6	11.5	8.3
PROSTATE CA	69	11.4	12.7	13.8	10.8
PROSTATE CA	70	2.0	4.9	2.5	2.8
PROSTATE CA	71	6.4	0.0	9.3	3.4
PROSTATE CA	72	5.4	15.4	6.3	7.0
PROSTATE CA	73	2.2	0.0	1.6	0.0

WO 93/09437

PCT/US92/09220

3/8
FIG. 2

<u>TISSUE TYPE</u>	<u>ASSAY 1*</u>	<u>ASSAY 2**</u>	<u>ASSAY 3***</u>
Breast normal 90-247	NT#	500	1250
Breast normal 90-252	7574	2705	5024
Breast normal 90-254	NT	1513	2789
Breast normal 90-264	NT	0	1685
Breast normal 90-268	139	NT	432
Breast cancer 90-256	438	NT	2750
Breast cancer 90-275	2000	NT	9429
Breast cancer 90-287	20222	7333	8600
Cervix normal 90-279	2500	NT	12571
Cervical cancer 90-8083	12666	NT	70680
Colon normal 90-253	1009	NT	1689
Colon cancer 90-250	1450	NT	4275
Kidney normal 90-259	4250	NT	4275
Kidney cancer 90-289	2407	NT	5796
Liver normal	2154	614	202
Liver normal 90-451	NT	131	420
Liver cancer	2227	0	932
Met liver 90-403	NT	300	1133
Lung normal 90-248	4391	NT	6636
Lung normal 90-246	4200	NT	10000
Lung normal 90-107	NT	4166	388
Lung normal 90-118	NT	650	1200
Lung cancer 90-095	NT	5357	16077
Lung cancer 90-121	NT	>12000	40771
Ovarian cancer	8621	6517	2760
Ovarian cancer 90-260	6900	NT	20680
Ovarian cancer 90-291	2768	NT	5750
Ovarian cancer 90-291	NT	10909	14454
Uterine cancer 90-277	6574	NT	70684
Uterus normal 90-295	6574	NT	41444
average normal	3447	1284	5759
average cancer	9442	7069	26321

* Assay 1 is 107.7 solid phase and 307.33 soluble phase.

** Assay 2 is 107.7 solid phase and 302.29 soluble phase.


*** Assay 3 is 302.18 solid phase and 302.22 soluble phase.

NT means not tested.

WO 93/09437

PCT/US92/09220

4 / 8

FIG. 3

WO 93/09437

PCT/US92/09220

5/8




Fig. 4A

WO 93/09437

PCT/US92/09220

6/8




Fig. 4B

SUBSTITUTE SHEET

WO 93/09437

PCT/US92/09220

7/8





Fig. 5

WO 93/09437

PCT/US92/09220

8 / 8

FIG. 6**FIG. 7**